Amgen Inc.
| Company type | Public |
|---|---|
| Industry | Biotechnology, Pharmaceuticals |
| Founded | 1980 |
| Founders | George Rathmann, Gordon Binder, William K. Bowes Jr. |
| Headquarters | Thousand Oaks, California , United States |
Key people | Robert A. Bradway (Chairman & CEO) |
| Products | Neulasta, Enbrel, Prolia, Xgeva, Otezla, Aranesp, EVENITY, KYPROLIS, Repatha |
| Website | www |
Amgen Inc. is an American multinational biotechnology company headquartered in Thousand Oaks, California. Founded in 1980, Amgen was one of the first biotechnology companies to become highly successful, pioneering the development and manufacturing of therapeutic proteins. The company focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives.
History[edit | edit source]
Amgen was founded in 1980 by George Rathmann, Gordon Binder, and William K. Bowes Jr., with the aim of harnessing the power of recombinant DNA technology for therapeutic purposes. The company's name, originally Applied Molecular Genetics, was soon shortened to Amgen. It quickly became a leader in the biotech industry, with the development of Erythropoietin (EPO) for anemia associated with chronic kidney failure as one of its first major successes.
Products[edit | edit source]
Amgen's product portfolio includes a wide range of treatments for oncology, kidney disease, bone disease, cardiovascular disease, and inflammatory diseases. Notable products include:
- Neulasta, a pegylated form of filgrastim used to decrease the incidence of infection in patients with non-myeloid cancer.
- Enbrel, a tumor necrosis factor inhibitor used in the treatment of rheumatoid arthritis and other autoimmune diseases.
- Prolia and Xgeva, both targeting the RANKL pathway to treat and prevent various bone-related conditions.
- Otezla, for the treatment of psoriasis and psoriatic arthritis.
- Aranesp, a synthetic form of erythropoietin for the treatment of anemia associated with chronic renal failure.
Research and Development[edit | edit source]
Amgen's commitment to research and development (R&D) is evident in its extensive pipeline of potential new therapies, including treatments for cancer, cardiovascular disease, and inflammatory diseases. The company invests heavily in R&D to discover and develop innovative medicines that address serious illnesses.
Corporate Responsibility[edit | edit source]
Amgen is dedicated to ethical business practices and corporate responsibility. It focuses on environmental sustainability, ethical conduct, and community engagement. The company's philanthropic efforts include supporting science education and patient advocacy programs.
Controversies[edit | edit source]
Like many pharmaceutical and biotechnology companies, Amgen has faced its share of controversies, including legal challenges and ethical debates over drug pricing and access to treatments. However, the company continues to work towards addressing these challenges through various initiatives and programs.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD
